Although the clinical relevance of this epigenetic heterogeneity in sarcoma remains to be clarified, recent studies have highlighted the potential of epigenetic therapies in OS and EwS: Selective inhibition of BET bromodomain epigenetic signaling interferes with the bone‐associated tumor's vicious cycle in OS and inhibits the oncogenic transcription factor EWSR1‐FLI1 in EwS (Lamoureux et al, 2014; Jacques et al, 2016; Baud'huin et al, 2017). This evidence concerns the gene FLI1 and neoplasm.